Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26167150 | 0.85 | SIGMAR1 (0.59) | SIGMAR1TSHRCYP2D6CYP3A4MEN1 | |
| SCHEMBL4289979 | 0.84 | LMNA (0.50) | SIGMAR1TSHRCYP2D6CYP3A4MEN1 | |
| SCHEMBL28550325 | 0.83 | GAA (0.53) | SIGMAR1TSHRCYP2D6CYP3A4GAA | |
| SCHEMBL24801949 | 0.83 | SIGMAR1 (0.51) | SIGMAR1TSHRCYP2D6CYP3A4GAA | |
| SCHEMBL24801905 | 0.83 | SIGMAR1 (0.51) | SIGMAR1TSHRCYP2D6CYP3A4GAA | |
| SCHEMBL29156328 | 0.83 | SIGMAR1 (0.51) | SIGMAR1TSHRCYP2D6CYP3A4GAA | |
| SCHEMBL11787686 | 0.81 | SIGMAR1 (0.60) | SIGMAR1POLB | |
| SCHEMBL20803931 | 0.81 | IDH1 (0.46) | SIGMAR1MEN1KMT2AALDH1A1 | |
| SCHEMBL24803408 | 0.80 | SIGMAR1 (0.49) | SIGMAR1TSHRCYP2D6CYP3A4GAA | |
| SCHEMBL24802024 | 0.80 | SIGMAR1 (0.49) | SIGMAR1TSHRCYP2D6CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2847191-B1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-06-15 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| EP-2760862-B1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2015-10-21 | — | — | EP | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133181-B2 | Substituted 6-(4-hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2015-05-14 | — | — | US | disclosed |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-04-04 | — | — | US | disclosed |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-04-04 | — | — | US | disclosed |
| WO-2013045413-A1 | 6-(4-HYDROXY-PHENYL)-3-ALKYL-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI (FR) | 2013-04-04 | — | — | WO | disclosed |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-04-04 | — | — | US | disclosed |
| CN-101917981-B | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP | 2012-11-14 | — | — | CN | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2208728-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 -HYDROXYSTEROID DEHYDROGENASE | Institute Of Medicinal Molecular Design, Inc. (JP) | 2010-07-21 | — | — | EP | disclosed |
| CN-101404987-A | Use of sulfonamide derivatives for the treatment of disorders of the surrogate and nervous systems | SMITHKLINE BEECHAM CORP (US) | 2009-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133432-A1 | SUBSTITUTED 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K19 | SIGMAR1 3451/4885TSHR 1883/4885CYP2D6 1632/4885 |
| US-20130085128-A1 | 6-(4-Hydroxy-phenyl)-3-alkyl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP3K6, MAP4K2 | SIGMAR1 3169/4885TSHR 1581/4885CYP2D6 1945/4885 |
| US-20100234363-A1 | HETEROCYCLIC DERIVATIVE HAVING INHIBITORY ACTIVITY ON TYPE-I 11 DATA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD11B2, HSD3B1 | SIGMAR1 761/4885TSHR 3851/4885CYP2D6 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.